Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03297424 | A Study of PLX2853 in Advanced Malignancies. | completed | Phase 1 | 49 | Opna Bio LLCINDUSTRY | 1 | Jul 25, 2022 | clinicaltrials |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy |
| terminated |
| Phase 1 |
| 49 |
| Genocea Biosciences, Inc.INDUSTRY |
| 1 |
| Jul 15, 2022 |
| clinicaltrials |
| NCT03080311 | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors | completed | Phase 1 | 50 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 28 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 12, 2022 | clinicaltrials |
| NCT04041011 | A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients | completed | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | terminated | Phase 1 | 10 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04346914 | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT03411915 | A Study of XmAb®18087 in Subjects With NET and GIST | completed | Phase 1 | 62 | Xencor, Inc.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT03147768 | Laser Tissue Welding - Distal Pancreatectomy Sealing Study(LTW) | completed | Phase 1 | 11 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02584829 | Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | terminated | Phase 1 / Phase 2 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02446704 | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 66 | Zofia PiotrowskaOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT01218555 | Study of Everolimus (RAD001) in Combination With Lenalidomide | completed | Phase 1 | 44 | Emory UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05158491 | Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC | unknown | Phase 1 / Phase 2 | 63 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04318561 | Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors(PET) | completed | Phase 1 / Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | terminated | Phase 1 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 27, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT05001412 | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC | unknown | Phase 1 | 36 | Zhou ChengzhiOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03898791 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | completed | Phase 1 | 48 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 5, 2021 | clinicaltrials |
| NCT03086239 | A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer | completed | Phase 1 | 29 | AbbVieINDUSTRY | 1 | Aug 3, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT03361384 | Alcohol and Implicit Process in Sexual Risk Behavior in MSM | completed | Phase 1 | 260 | Syracuse UniversityOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT01208051 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | completed | Phase 1 / Phase 2 | 127 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT01840579 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | completed | Phase 1 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04890795 | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 237 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT03227016 | Study in Patients With SCLC of Veliparib in Combination With Topotecan | unknown | Phase 1 | 30 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02514824 | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | completed | Phase 1 / Phase 2 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00446082 | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease | completed | Phase 1 | 85 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT00466466 | Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 21, 2020 | clinicaltrials |
| NCT01263353 | Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(COOPERATE-1) | completed | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01364415 | Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) | completed | Phase 1 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04659785 | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | unknown | Phase 1 / Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT00765973 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 14 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jul 25, 2022source: clinicaltrials